Why Glaukos Stock Zoomed Nearly 19% Higher Today
Glaukos (NYSE: GKOS), a specialty healthcare company that concentrates on eye disorders, enjoyed a very healthy pop in its share price on Wednesday. This followed the company's latest clinical update. Investors traded the stock up by almost 19%.
That update was about iDose TR, a drug aimed at treating intraocular pressure in ocular hypertension.
In a complementary pair of phase 3 trials, iDose TR achieved its primary efficacy endpoints through a three-month treatment cycle. The drug also demonstrated a favorable safety profile and was extremely well tolerated, Glaukos said.
Source Fool.com
